India, May 29 -- This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple therapeutic areas, including primary biliary cholangitis, fatigue, resectable lung cancer, and moderate-to-severe atopic dermatitis.
Let's unpack the specifics.
FDA Approvals and Rejections
FDA Approves AstraZenca's IMFINZI + BCG Combo for High-Risk NMIBC
AstraZeneca (AZN) secured FDA approval for IMFINZI (durvalumab) combined with BCG for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC), supported by positive Phase 3 POTOMAC data showing a significant disease-free survival benefit and a 32% reduction in recurrence or death versus BCG alone....